Non-Hodgkin Lymphoma Archives - Page 9 of 10

The continuous decline in cancer deaths over the past 25 years was attributed to improvements in scr

Hematologic Cancers, Lymphoma, Pediatric Cancer

“Real-World” Hospitalization Data on Patients Receiving CAR-T Cell Therapy

By

March 7, 2019

An investigation of a large performance improvement clinical database revealed that most individuals receiving CAR-T have diagnoses of ALL or large B-cell lymphoma.

Several new regimen options for the treatment of as well as the recently FDA-approved combination dr

Hematologic Cancers

Ambient Benzene Exposure and Risk of Hematologic Malignancies

By

Susan Moench, PhD, PA-C

February 19, 2019

Researchers examined low-level estimates of ambient benzene to investigate whether it was associated with increased cancer incidence across a nationwide cohort.

One study’s results may be especially relevant for patients eligible for treatment discontinuation.

Lymphoma

Ibrutinib Plus Nivolumab in 4 Cohorts of Patients With R/R NHL or CLL

By

Susan Moench, PhD, PA-C

February 14, 2019

According to results of an exploratory study, patients with Richter transformation may benefit from treatment with ibrutinib plus nivolumab.

The heterogeneity of kidney cancer makes each of the tumors unique and treatment decisions based on

Lymphoma

FDA Approves Mogamulizumab-kpkc for Rare Subtypes of Non-Hodgkin Lymphoma

By

James Nam, PharmD

August 9, 2018

Mogamulizumab-kpkc (Poteligeo), a humanized monoclonal antibody that targets CCR4, provides a new treatment option for patients with MF and is the first FDA-approved therapy for SS.

A recent meta-analysis including patients from 7 trials shows that MR improves overall survival amon

Lymphoma

Interim PET Scans May Predict Survival Outcomes in Non-Hodgkin Lymphoma

By

James Nam, PharmD

May 14, 2018

Being able to identify which patients would respond to standard therapies allows for early adjustment in treatment and improves outcomes.

Patients younger than 50 years with NSCLC were more likely to have a targetable genomic alteration.

Lymphoma

Evaluating the Relationship Between Q Fever and Non-Hodgkin Lymphoma

By

James Nam, PharmD

April 10, 2018

Findings from a previous study suggested that Q fever may significantly increase a person’s risk of nHL.

Lymphoma

Obinutuzumab Plus Bendamustine Prolongs PFS in Rituximab-Refractory Non-Hodgkin Lymphoma

By

James Nam, PharmD

April 5, 2018

Previous findings showed that patients obinutuzumab plus bendamustine prolonged progression-free survival, but data was immature at the time of analysis.

Dual expression of MYC and BCL2 was associated with worse survival among patients with GCB-like DLBC

Lymphoma

Poorer DLBCL Survival Outcomes Linked to Dual Expression of MYC, BCL2

By

Megan Garlapow, PhD

June 5, 2017

Dual expression of MYC and BCL2 was associated with worse survival among patients with GCB-like DLBCL, though this status was not associated with any outcomes among patients with ABC-like DLBCL.

Data support use of bendamustine for patients treated with several lines of therapy, but whether thi

Lymphoma

In Focus: Bendamustine for Non-Hodgkin Lymphomas

By

Alexander M. Castellino, PhD

April 28, 2017

Data support use of bendamustine for patients treated with several lines of therapy, but whether this drug should be used in the first line is open to question.

More studies are needed to determine the association between periodontal disease and non-Hodgkin lym

Lymphoma

Periodontal Disease: A Risk Factor for Non-Hodgkin Lymphoma?

By

Andrea S. Blevins Primeau, PhD, MBA

March 31, 2017

More studies are needed to determine the association between periodontal disease and non-Hodgkin lymphoma.